Short Interest in Achilles Therapeutics plc (NASDAQ:ACHL) Declines By 25.1%

Achilles Therapeutics plc (NASDAQ:ACHL) was the recipient of a large drop in short interest in October. As of October 31st, there was short interest totalling 159,300 shares, a drop of 25.1% from the October 15th total of 212,600 shares. Currently, 0.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 642,000 shares, the days-to-cover ratio is currently 0.2 days.

Hedge Funds Weigh In On Achilles Therapeutics

Large investors have recently modified their holdings of the company. XTX Topco Ltd boosted its stake in Achilles Therapeutics by 239.4% in the second quarter. XTX Topco Ltd now owns 51,660 shares of the company’s stock worth $42,000 after buying an additional 36,441 shares in the last quarter. Acadian Asset Management LLC bought a new stake in shares of Achilles Therapeutics in the 1st quarter worth approximately $350,000. StemPoint Capital LP purchased a new stake in shares of Achilles Therapeutics in the 1st quarter valued at $1,732,000. Ikarian Capital LLC bought a new position in shares of Achilles Therapeutics during the 1st quarter valued at $1,804,000. Finally, BML Capital Management LLC grew its holdings in shares of Achilles Therapeutics by 555.8% during the 3rd quarter. BML Capital Management LLC now owns 4,100,002 shares of the company’s stock valued at $4,182,000 after purchasing an additional 3,474,828 shares during the last quarter. 56.38% of the stock is owned by hedge funds and other institutional investors.

Achilles Therapeutics Stock Performance

NASDAQ ACHL opened at $1.07 on Friday. Achilles Therapeutics has a 52-week low of $0.63 and a 52-week high of $1.76. The company has a fifty day moving average of $0.94 and a 200-day moving average of $0.87. The company has a market capitalization of $43.97 million, a P/E ratio of -0.64 and a beta of 1.35.

Achilles Therapeutics (NASDAQ:ACHL) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.41). As a group, analysts forecast that Achilles Therapeutics will post -1.7 EPS for the current fiscal year.

Achilles Therapeutics Company Profile

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.